SOURCE: Generex Biotechnology

May 14, 2007 09:40 ET

Generex Biotechnology Receives Strong Interest From Leading National and Regional Retailers, Drug Stores and Wholesalers for Its OTC Line

Generex Preparing for North America and International Expansion and Launch of Its OTC line

WORCESTER, MA -- (MARKET WIRE) -- May 14, 2007 -- Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that it generated strong interest from leading national and regional retailers, drug stores and wholesalers for its OTC line of products at The Home Health Care Efficient Program Planning Session. The products include Glucose RapidSpray™, BaBOOM!™ and GlucoBreak™. The Session was held from May 6-9th at the Doral Tesoro Hotel & Golf Club in Fort Worth, Texas.

As a consequence of the meetings, Generex expects to expand Glucose RapidSpray™ nationwide, and launch BaBOOM!™ and GlucoBreak™ in several of the largest national and regional retailers and drug store chains, which comprise well over 20,000 stores nationwide. In addition to its national distribution strategy in the USA and Canada, the Company is now expanding its distribution network in other markets around the world for its OTC line of products.

"We believe the market opportunity is substantial, and were pleased that there was such significant demand for our OTC products from some of the largest retailers in North America," said Anna Gluskin, President and Chief Executive Officer of Generex Biotechnology. "With sales of energy-related drinks and weight-loss products among the fastest growing categories of products, we believe that the opportunity for our OTC product line is substantial."

Glucose RapidSpray™ is an innovative alternative for people who want additional glucose in their diet. The product delivers a fat-free, low-calorie glucose formulation directly into the buccal cavity using the Company's proprietary buccal drug delivery technologies. Glucose RapidSpray™ is simple to carry and use. Glucose RapidSpray™ is already being marketed in the United States and Canada and is available in a number of leading retail chains. For more information visit

BaBOOM!™ is an innovative, convenient and great-tasting instant energy spray that enhances energy levels for sports, work, study, travel and overall fatigue. Main ingredients include Glucose, Caffeine, Ginseng, Vitamin C, Vitamin B1, Vitamin B3, Vitamin B6, Vitamin B12. BaBOOM!™ is fat free, has under 5 calories per serving and comes in watermelon flavor. For more information visit

Energy products have become a $3 billion business since their introduction in the United States eight years ago, and are expected to accelerate profit growth for the beverage industry more than any other drink category in the next few years.

GlucoBreak™ is an innovative, convenient, great-tasting and fat-free glucose spray that is used as an aid for diets. GlucoBreak™ is used between meals as part of a daily diet routine, during exercise and before bedtime. For more information visit

According to Marketdata Enterprises, Inc. (, a leading market research publisher of service industry studies, the total U.S. weight-loss market generated sales of $55.4 billion in 2006 and should reach $58.7 billion this year and $68.7 billion by 2010. It is estimated that there are 72 million dieters -- about 70% of whom try to lose weight by themselves.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, oral insulin (Generex Oral-lyn™), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at or the Antigen Express website at

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Contact Information

  • Contact:
    For more information, please contact:

    For Generex:
    Shayne Gilliatt
    800-391-6755 or 416-364-2551

    Andrew Hellman
    CEOcast, Inc.